Not Yet RecruitingPhase 2

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

China120 participantsStarted 2025-12-19

Plain-language summary

The GS3-007a Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, three-way crossover trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Sex;
✓. Age;
✓. BMI;
✓. (If feasible) Estrogen use and administration route (oral, transdermal) in females:

Exclusion criteria

✕. Chronic congestive heart failure (New York Heart Association (NYHA) Class III or higher);
✕. Other significant cardiovascular/cerebrovascular diseases, e.g., uncontrolled severe hypertension, severe arrhythmia, stroke or transient ischemic attack (TIA), or confirmed coronary artery disease;
✕. Traumatic brain injury (TBI).

What they're measuring

ROC curves and the area under the curve (AUC) of the ROC curves

Timeframe: up to 120minutes

Trial details

NCT IDNCT07259564

SponsorChangchun GeneScience Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05-12

Contact for this trial

Hui Pan, MD

010-69156114 panhui20111111@163.com

View on ClinicalTrials.gov More Adult Growth Hormone Deficiency (AGHD) trials